I mmune globulin (IG) products licensed in the United
States are required to meet minimum potency levels, which include a specification for antibodies to measles virus, defined in the Code of Federal Regulations subpart on Immune Globulin Human Food and Drug Administration regulation 21 CFR 640.104. 1 There is a high seroprevalence of measles antibodies in the US population, 2 which is the source of plasma used to manufacture IG products. However, the plasma donor population is changing over time from persons with immunity to disease to persons with predominantly vaccine-induced measles immunity. Vaccination produces lower levels of measles virus neutralizing antibodies compared to wild-type infection, resulting in a decline in the measles antibody levels of IG products over time. 3, 4 This decline in measles virus neutralizing antibody levels prompted thorough review in 2007 by stakeholders including the Food and Drug Administration, patient groups, IG manufacturers, the Blood Products Advisory Committee, and the Plasma Protein Therapeutics Association. 5 Based on this review, the Blood Products Advisory
Committee advised in favor of lowering the measles antibody specification from 0.60 to 0.48× Center for Blood Evaluation and Research (CBER) Reference 176 (adjusted for immunoglobulin G [IgG] concentration). 5 IG products at the 0.48× CBER Reference 176 are expected to provide levels considered seroprotective when dosed at the minimal prescribing levels.
Since the 2007 review, the level of measles antibodies in the plasma of the donor population has continued to further decline. 4 There is a proposal to lower the measles specification further to 0.30× CBER reference standard 176 (adjusted for protein concentration). However, before lowering the specification, the Food and Drug Administration has considered requesting data from manufacturers showing measles antibody trough levels, and performing modeling to predict the serum levels of measles antibodies at the lower proposed specification. 6 A clinical study was conducted that examined troughlevel measles neutralizing antibodies measured in 10 pediatric patients with primary immunodeficiency disease (PID; ages 2-16) treated with IG administered both intravenously and subcutaneously. Furthermore, modeling was performed to predict the lowest possible trough measles antibody levels assuming potency of the IG product at 0.48 and 0.30× CBER Reference 176 specifications.
MATERIALS AND METHODS
The clinical study performed in pediatric subjects was conducted according to protocol "An Open-label, Single-sequence, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects with Primary Immunodeficiency" (NCT01465958), and overall results have been published. 7 Gamunex-C (Grifols)
is a 10% IG (human) preparation. The study was a Phase 4, multicenter, open-labeled, single-sequence, crossover study in patients aged 2 to 16 with PID. The study included intravenous (IV) infusions of Gamunex-C (200-600 mg/kg per infusion) administered with a dosing interval of every 3 or 4 weeks. Upon completion of the IV phase, subjects entered the subcutaneous (SC) phase, receiving weekly SC-administered Gamunex-C for 12 weeks. The weekly SC dose of Gamunex-C was calculated using the total IV dose (mg/kg) divided by the IV dosing interval (3 or 4 weeks) times a 1.37 conversion factor. The conversion factor of 1.37 was determined based on published studies for subcutaneously administered IgG. 7 Before the IV phase of the study, patients were required to have a stable IV dose for a minimum of 3 months to assure consistent levels of IgG. Blood samples for pharmacokinetic assessments of plasma total IgG concentrations for IV-administered Gamunex-C were collected during the IV phase immediately before the first infusion and at a number of time points from 1 hour to 28 days, with the last sample being collected just before the second IV infusion, at 21 or 28 days, depending on dosing interval. The last sample before the second IV infusion was also tested to determine measles antibody trough levels. Blood samples for pharmacokinetic assessments for SC-administered Gamunex-C were collected during the SC phase immediately before the 12th infusion (12 weeks), 3 days after the 12th infusion, and 7 days after the 12th infusion. The sample taken 7 days after the 12th infusion was also tested for SC measles antibody trough levels.
The measles neutralization assay is based on the ability to prevent measles virus infection in Vero cells adapted from a neutralization method previously described. 8 
RESULTS
Trough level measurements of measles antibody levels from 10 patients following both IV and SC administration were included in this evaluation. For those 10 patients, mean IgG results are shown in Fig. 1 . For IV administration, IgG levels increase rapidly upon administration, reaching maximum concentrations at 1 hour after infusion. Mean trough IgG levels for IV-administered Gamunex-C were 1001 mg/dL and 884 mg/dL for patients dosed at 3-and 4-week intervals, respectively, with an overall mean trough IgG of 980 mg/dL. For SCadministered Gamunex-C, there is less overall spread between trough and maximum IgG levels, with mean trough levels at 1306 mg/dL. The measles antibody levels for individual patients measured at trough levels are shown in Fig. 2 . For IV administered Gamunex-C, mean measles antibody trough levels were at 1.44 and 1.00 IU/mL for patients dosed at 3-and 4-week intervals, respectively, with an overall mean trough level of 1.35 IU/mL. For SC-administered Gamunex-C, the mean measles antibody trough level was 1.72 IU/mL. Mean antibody trough levels are presented in Table 1 for both IV and SC administration.
Using the mean trough measles antibody levels from this study, worst-case trough antibody levels were modeled based on the current worst-case (lowest) potency and dosing. Trough levels were calculated using a linear adjustment downward for actual potency of the Gamunex-C batch used in the study compared to the specification (actual potency of 0.86× CBER Reference 176 versus specification of 0.48× CBER Reference 176), and using a linear adjustment for the lowest labeled dose (300 mg/kg vs. the actual dosing, which ranged from 300-600 mg/kg). Results are summarized in Table 2 . The calculated current worst-case measles antibody trough levels are 0.47 and 0.58 IU/mL for IV and SC administration, respectively. Also included in Table 2 are calculated ratios of the mean trough levels to the 0.12 IU/mL measles antibody level considered seroprotective. 9 Worst-case trough antibody levels were also modeled for a future case to account for a potential decrease in the potency requirement from the current 0.48× CBER Reference 176 to 0.30× CBER Reference 176. Trough levels were calculated using a linear adjustment downward from actual potency of the Gamunex-C batch used in the study compared to proposed lower specification (actual potency of 0.86× CBER 176 vs. specification of 0.30× CBER 176), and using a linear adjustment for proposed lowest dose (400 mg/kg vs. the actual dosing, which ranged from 300-600 mg/kg). The calculated future worst-case trough measles antibody levels are 0.39 and 0.48 IU/mL for IV and SC administration, respectively.
DISCUSSION
The profile of serum IgG is shown in Fig. 1 after administration of human IG for both IV and SC delivery. Trough levels are measured at the point where the circulating levels of IgG are at their lowest, just before infusion of the next dose. Trough measles antibody levels are important because they represent the lowest level of seroprotective antibody levels to the measles virus, with IV levels somewhat lower than SC levels.
The actual trough measles antibody levels measured in this study are shown in Fig. 2 . The average results are 11-fold or greater above the 0.12 IU/mL level considered protective. The 0.12 IU/mL level considered protective is based on study by Chen et al. 9 of a measles outbreak at Boston University in 1985. Pre-outbreak blood samples were available from a blood drive that occurred shortly before the outbreak. The 0.12 IU/mL protective level was determined by analysis of preexposure antibody titers with incidence of measles infection. It should be noted that the 0.12 level is considered protective for healthy individuals. The level considered protective for patients with PID is unknown, but a level of 0.24 IU/mL has been suggested, 10 which is a simple factor of two greater than 0.12 IU/mL. However, the 0.12 IU/mL protective level determined by Chen et al. has been used in previous modeling 3 and is cited in the Advisory Committee on Immunization Practices guidelines for measles following exposure prophylaxis, 11 and was thus selected for comparison to demonstrate protective levels of measles antibodies in this study.
In modeling worst-case trough measles antibody levels, two cases were selected. The first case is based on current product measles antibody levels and dosing. To determine the lowest appropriate dose, prescribing information for IG products licensed in the United States for use in PID was reviewed. Most IG products administered intravenously recommend a minimum dosing of 300 mg/kg for PID, including Bivigam (Biotest Pharmaceuticals Corporation), 12 Flebogama DIF (Grifols), 13 Gammagard Liquid (Baxalta US Inc.), 14 and Gamunex-C. 15 Maximum prescribed dosages range from 600 to 800 mg/kg and vary by product. The actual dosing used in the Gamunex-C in this study ranged from 300 to 600 mg/kg. At the minimum dosing of 300 mg/kg, the calculated average results are 3.9-and 4.0-fold above the 0.12 IU/mL protective level, for IV and SC dosing, respectively. For the second case, calculations were made based on lowering the measles specification on IG products to 0.30× CBER Reference 176. This assumes that the trends in measles antibody levels will continue to decline, and lowering the requirement will be necessary to assure that IG will meet the specification. The 400 mg/kg level selected for dosing is based on the recommendation of the Advisory Committee on Immunization Practices, which suggests that subjects already receiving IG IV therapy with a dose of at least 400 mg/kg body weight within 3 weeks before measles exposure should be sufficient to prevent measles infection.
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Similarly, the Gamunex-C prescribing information includes a minimum recommended IV dose of 400 mg/kg for those at risk of exposure to measles. 15 Using these worst-case conditions will provide an average of 3.2-and 4.0-fold above the 0.12 IU/mL protective level, for IV and SC dosing, respectively. The calculations used for the modeling assume a linear response between IG product dose and trough measles antibody levels. The linear relationship between IG dose and trough-level IgG is well established for both IV and SC administration, 16, 17 which supports this assumption.
The clinical study used as a basis for the modeling was in pediatric subjects. The pharmacokinetics and safety of Gamunex were found to be similar for pediatric and adult subjects when administered either intravenously or subcutaneously. 7, 18 The prescribing information for Gamunex reiterates the similarity of pharmacokinetics and safety between adults and pediatric patients and notes no differences in dosing requirements. 15 This supports the applicability of modeling to adults as well as pediatric patients. This modeling demonstrates that current measles antibody specification of 0.48× CBER Reference 176 is suitable to provide seroprotection for measles virus. In addition, if the specification of IG is lowered to 0.30× CBER Reference 176, trough levels will still be at or above levels that are seroprotective for measles, provided the minimum recommended IV dose of 400 mg/kg, or the equivalent SC dose is administered.
